Page last updated: 2024-09-05

sorafenib and Lymphoma, T-Cell, Cutaneous

sorafenib has been researched along with Lymphoma, T-Cell, Cutaneous in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gülow, K; Kießling, MK; Klemke, CD; Krammer, PH; Nicolay, JP; Schlör, T; Süss, D	1
Barbarotta, L; Cooper, D; Foss, F; Gibson, JF; Irizarry, D; Lansigan, F; Seropian, S	1

Other Studies

2 other study(ies) available for sorafenib and Lymphoma, T-Cell, Cutaneous

Article	Year
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget, 2017, Jul-11, Volume: 8, Issue:28 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat	2017
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British journal of haematology, 2014, Volume: 167, Issue:1 Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome	2014

Article

Year

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.

Oncotarget, 2017, Jul-11, Volume: 8, Issue:28

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat

2017

Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.

British journal of haematology, 2014, Volume: 167, Issue:1

Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2014